<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>Homotaurine</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>Homotaurine</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/thumb/f/f6/Homotaurine.svg/220px-Homotaurine.svg.png"/></li>
<li>Homotaurine, also known as Tramiprosate, is a sulfonic acid compound found naturally in seaweed and has been extensively studied for its potential therapeutic effects, particularly in Alzheimer's disease (AD). This survey note provides a detailed examination of its pharmacological actions, pharmacokinetics, dosage regimens, and safety profile, drawing from a wide range of scientific literature and clinical trial data available as of May 29, 2025.</li>
<li>Pharmacological Actions</li>
<li>Tramiprosate exhibits a multifaceted pharmacological profile, primarily targeting mechanisms implicated in AD pathology. The key actions include:</li>
<ul>
<li>Inhibition of Amyloid-β (Aβ) Aggregation: Tramiprosate binds to soluble Aβ, particularly at residues Lys16, Lys28, and Asp23, stabilizing monomers and reducing the formation of toxic oligomers and fibrillar plaques. This action is crucial as Aβ aggregation is a hallmark of AD, contributing to neuronal damage. Preclinical studies in transgenic mice have shown reduced plaque burden and decreased CSF Aβ levels, supporting its potential as a disease-modifying agent. (<a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/homotaurine">source</a>)</li>
<li>GABAergic Activity: Structurally similar to γ-amino butyric acid (GABA), Tramiprosate acts as a functional agonist at GABA-A receptors, which may contribute to its neuroprotective effects. This activity is thought to modulate neuronal excitability and provide protection against Aβ-induced neurotoxicity (<a href="https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2020.00614/full">source</a>). It also reduces caspase 3/7 and 9 activities in organotypic hippocampal slice cultures, suggesting a GABA-dependent neuroprotective mechanism. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7358344/">source</a>)</li>
<li>Anti-inflammatory Effects: Clinical studies, particularly in mild cognitive impairment (MCI) patients, have demonstrated reduced levels of inflammatory markers such as IL-18, indicating an anti-inflammatory role (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5724794/">source</a>). This action may mitigate the inflammatory component of AD pathology.</li>
<li>Neuroprotection: Beyond GABA-dependent pathways, Tramiprosate inhibits Aβ42-induced ERK1/2 activation through a GABA-independent mechanism, further enhancing its neuroprotective profile (<a href="https://pubmed.ncbi.nlm.nih.gov/28435985/">source</a>). This dual mechanism suggests broad protective effects against neuronal damage.</li>
<li>Promotion of Tau Polymerization: Interestingly, Tramiprosate promotes the polymerization of tau into non-toxic aggregates without affecting tau-microtubule binding, potentially reducing the formation of neurofibrillary tangles, another AD hallmark. (<a href="https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-2-17">source</a>)</li>
</ul>
<li>The time course of these actions is not fully detailed in the literature, but clinical studies indicate that effects on biomarkers like CSF Aβ levels are observable after three months of treatment, suggesting a gradual onset. (<a href="https://n.neurology.org/content/67/10/1757">source</a>)</li>
<li>Pharmacokinetics</li>
<li>Pharmacokinetic data for Tramiprosate are primarily derived from studies involving its prodrug, ALZ-801, due to its improved pharmacokinetic profile. Key parameters include:</li>
<ul>
<li>Half-life: Studies with ALZ-801 suggest a half-life for Tramiprosate of approximately 15-18 hours. For instance, a 2025 study reported a terminal phase elimination half-life of about 14.8 hours, while a 2018 study indicated around 18 hours (<a href="https://link.springer.com/article/10.1007/s40262-025-01482-8">Clinical Pharmacokinetics: Clinical Pharmacokinetics of Oral ALZ-801</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/29063518/">PubMed: Clinical Pharmacokinetics and Safety of ALZ-801</a>).</li>
<li>Bioavailability: Specific oral bioavailability for Tramiprosate is not directly available, but for ALZ-801, an estimated oral bioavailability of approximately 52% was reported in a 2018 study, suggesting efficient absorption and conversion to active moieties (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5814546/">source</a>). Given ALZ-801's design to improve upon Tramiprosate's pharmacokinetics, the bioavailability of Tramiprosate itself may be lower, but exact figures are lacking.</li>
<li>Metabolism and Excretion: Tramiprosate is metabolized to 3-sulfopropanoic acid (3-SPA), an endogenous metabolite with anti-Aβ activity, and is primarily eliminated via renal excretion, with plasma exposures inversely correlated with estimated glomerular filtration rate (eGFR) (<a href="https://link.springer.com/article/10.1007/s40262-025-01482-8">source</a>).</li>
</ul>
<li>Dosage Regimens</li>
<ul>
<li>Range of Doses Tested: Doses in clinical studies ranged from 50 mg to 150 mg twice daily (BID). For example, a phase II study randomized patients to 50 mg, 100 mg, or 150 mg BID for three months, with an open-label extension at 150 mg BID for 17 months (<a href="https://www.neurology.org/doi/10.1212/01.wnl.0000244346.08950.64">source</a>). Phase III trials, such as the Alphase Study, used 100 mg and 150 mg BID for 78 weeks (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3258678/">source</a>).</li>
<li>Minimum Effective Dose: The minimum effective dose appears to be around 100 mg BID, as this dose showed a dose-dependent reduction in CSF Aβ42 levels in phase II studies, suggesting therapeutic activity (<a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/homotaurine">source</a>). Lower doses like 50 mg BID showed less pronounced effects.</li>
<li>Maximum Safe Dose: The maximum tested dose in humans is 150 mg BID, which was generally well-tolerated, with adverse events primarily gastrointestinal, such as nausea and vomiting, leading to discontinuation in about 3.6% of patients (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7358344/">source</a>). No amyloid-related imaging abnormalities (ARIAs) were observed, indicating a favorable safety profile at this dose.</li>
<li>LD50 and Toxicity Thresholds: Specific LD50 values for Homotaurine are not publicly available in the literature reviewed. Preclinical toxicology data are sparse, with studies focusing more on efficacy and safety in animal models rather than acute toxicity. Given its use in clinical trials at doses up to 150 mg BID without serious adverse events, it is considered safe at therapeutic levels, but higher doses have not been tested in humans, making the toxicity threshold unclear (<a href="https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2020.00614/full">source</a>).</li>
</ul>
<li>Safety Profile</li>
<ul>
<li>Common Adverse Effects: The most frequent adverse events are gastrointestinal, including nausea, vomiting, and weight loss, which are dose-dependent but not significantly different from placebo at 100 mg BID (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3258678/">source</a>). Syncope was also reported in some cases.</li>
<li>Mortality and Serious Events: In the Alphase Study, mortality rates were 4.0% for placebo, 2.8% for 100 mg BID, and 2.3% for 150 mg BID, with no significant difference, suggesting no increased risk at therapeutic doses (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7358344/">source</a>).</li>
<li>Subgroup Safety: APOE4 carriers, particularly homozygotes, showed a similar safety profile, with no increased incidence of vasogenic edema compared to non-carriers (<a href="https://pubmed.ncbi.nlm.nih.gov/29199323/">source</a>).</li>
</ul>
<li>Given the lack of LD50 data and the focus on chronic safety in elderly patients, the point at which Tramiprosate becomes dangerously toxic is not established, but clinical data suggest it remains safe within the tested range of 50-150 mg BID.</li>
<li>Summary Table of Key Parameters</li>
<ul>
<li><table>
<tr>
<th>Parameter</th>
<th>Details</th>
</tr>
<tr>
<td>Half-life</td>
<td>Approximately 15-18 hours (from ALZ-801 studies)</td>
</tr>
<tr>
<td>Oral Bioavailability</td>
<td>Estimated ~52% (from ALZ-801, exact for Tramiprosate not specified)</td>
</tr>
<tr>
<td>Minimum Effective Dose</td>
<td>Likely 100 mg BID, based on CSF Aβ42 reduction</td>
</tr>
<tr>
<td>Maximum Safe Dose</td>
<td>150 mg BID, well-tolerated with gastrointestinal side effects</td>
</tr>
<tr>
<td>LD50</td>
<td>Not publicly available, safety established at therapeutic doses</td>
</tr>
<tr>
<td>Common Side Effects</td>
<td>Nausea, vomiting, weight loss, dose-dependent</td>
</tr>
</table></li>
</ul>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main></body></html>